202 related articles for article (PubMed ID: 17333336)
1. Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer.
van der Groep P; Hoelzel M; Buerger H; Joenje H; de Winter JP; van Diest PJ
Breast Cancer Res Treat; 2008 Jan; 107(1):41-7. PubMed ID: 17333336
[TBL] [Abstract][Full Text] [Related]
2. FANCD2 protein is expressed in proliferating cells of human tissues that are cancer-prone in Fanconi anaemia.
Hölzel M; van Diest PJ; Bier P; Wallisch M; Hoatlin ME; Joenje H; de Winter JP
J Pathol; 2003 Oct; 201(2):198-203. PubMed ID: 14517836
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
5. Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice.
Houghtaling S; Granville L; Akkari Y; Torimaru Y; Olson S; Finegold M; Grompe M
Cancer Res; 2005 Jan; 65(1):85-91. PubMed ID: 15665282
[TBL] [Abstract][Full Text] [Related]
6. FANCD2 associated with sporadic breast cancer risk.
Barroso E; Milne RL; Fernández LP; Zamora P; Arias JI; Benítez J; Ribas G
Carcinogenesis; 2006 Sep; 27(9):1930-7. PubMed ID: 16679306
[TBL] [Abstract][Full Text] [Related]
7. The molecular biology of Fanconi anemia.
Tamary H; Bar-Yam R; Zemach M; Dgany O; Shalmon L; Yaniv I
Isr Med Assoc J; 2002 Oct; 4(10):819-23. PubMed ID: 12389351
[TBL] [Abstract][Full Text] [Related]
8. FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.
Kachnic LA; Li L; Fournier L; Ferraiolo N; Dahm-Daphi J; Borgmann K; Willers H
Cancer Lett; 2011 Jun; 305(1):86-93. PubMed ID: 21414716
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
Pejovic T; Yates JE; Liu HY; Hays LE; Akkari Y; Torimaru Y; Keeble W; Rathbun RK; Rodgers WH; Bale AE; Ameziane N; Zwaan CM; Errami A; Thuillier P; Cappuccini F; Olson SB; Cain JM; Bagby GC
Cancer Res; 2006 Sep; 66(18):9017-25. PubMed ID: 16982743
[TBL] [Abstract][Full Text] [Related]
10. High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer.
van der Groep P; Bouter A; Menko FH; van der Wall E; van Diest PJ
Breast Cancer Res Treat; 2008 Oct; 111(3):475-80. PubMed ID: 18030615
[TBL] [Abstract][Full Text] [Related]
11. Expression and prognostic significance of Fanconi anemia group D2 protein and breast cancer type 1 susceptibility protein in familial and sporadic breast cancer.
Feng L; Jin F
Oncol Lett; 2019 Apr; 17(4):3687-3700. PubMed ID: 30881493
[TBL] [Abstract][Full Text] [Related]
12. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
13. Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer.
Fagerholm R; Sprott K; Heikkinen T; Bartkova J; Heikkilä P; Aittomäki K; Bartek J; Weaver D; Blomqvist C; Nevanlinna H
Ann Oncol; 2013 Nov; 24(11):2780-5. PubMed ID: 23897704
[TBL] [Abstract][Full Text] [Related]
14. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.
Lewis AG; Flanagan J; Marsh A; Pupo GM; Mann G; Spurdle AB; Lindeman GJ; Visvader JE; Brown MA; Chenevix-Trench G;
Breast Cancer Res; 2005; 7(6):R1005-16. PubMed ID: 16280053
[TBL] [Abstract][Full Text] [Related]
15. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
Hussain S; Witt E; Huber PA; Medhurst AL; Ashworth A; Mathew CG
Hum Mol Genet; 2003 Oct; 12(19):2503-10. PubMed ID: 12915460
[TBL] [Abstract][Full Text] [Related]
16. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
Levran O; Attwooll C; Henry RT; Milton KL; Neveling K; Rio P; Batish SD; Kalb R; Velleuer E; Barral S; Ott J; Petrini J; Schindler D; Hanenberg H; Auerbach AD
Nat Genet; 2005 Sep; 37(9):931-3. PubMed ID: 16116424
[TBL] [Abstract][Full Text] [Related]
17. Expression of FANCD2 in sporadic breast cancer and clinicopathological analysis.
Zhang B; Chen R; Lu J; Shi Q; Zhang X; Chen J
J Huazhong Univ Sci Technolog Med Sci; 2010 Jun; 30(3):322-5. PubMed ID: 20556575
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer and Fanconi anemia: what are the connections?
Zdzienicka MZ; Arwert F
Trends Mol Med; 2002 Oct; 8(10):458-60. PubMed ID: 12383764
[TBL] [Abstract][Full Text] [Related]
19. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
Arnes JB; Bégin LR; Stefansson I; Brunet JS; Nielsen TO; Foulkes WD; Akslen LA
J Clin Pathol; 2009 Feb; 62(2):139-46. PubMed ID: 18682421
[TBL] [Abstract][Full Text] [Related]
20. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
Pinilla SM; Honrado E; Hardisson D; Benítez J; Palacios J
Breast Cancer Res Treat; 2006 Sep; 99(1):85-90. PubMed ID: 16541313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
